Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)

Autor: FA Medeiros, TR Walters, M Kolko, Coote, Michael, M Bejanian, ML Goodkin, Q Guo, J Zhang, MR Robinson, RN Weinreb, A Agar, R Bathijia, L Liu, T Roberts, C Faschinger, C Vass, N Collignon, AC Alves Pereira, R Belfort De Mattos, FJ Dantas, MJ Lopes Da Silva, F Kanadani, L Magacho Dos Santos Silva, T Prata, D Bach-Holm, J Lai, C Tham, G Bátor, L Szalczer, B Varsányi, E Blumenthal, O Geyer, S Lavartovsky, T Pedut-Kloizman, N Shoham-Hazon, S Lujan, B Abela, RE Ang, EU Leuenberger, H Uy, MI Yap-Veloso, P Fryczkowski, P Jurowski, B Kalużny, J Kalużny, M Misiuk-Hojlo, K Raczynska, W Tomczyk-Dorozynska, J Wasyluk, S Zalewski, T Zarnowski, JG Feijoó, R Giménez-Gómez, EM Griño, AA López, MG Miralles, JM Moreno, V Polo, EC Taulet, BP Zúñiga, YY Chen, YC Lee, L Alpern, MS Berlin, J Brubaker, D Caldwell, A Camp, LB Cantor, R Caronia, CJ Crane, D Day, E Duzman, J Elfervig, S El-Harazi, R Evans, AC Fisher, WJ Flynn, CS Foster, R Frenkel, R Goyal, R Gross, PJ Hartman, WL Haynes, G Jerkins, J Kim, M Kim, B Kwapiszeski, B Lambright, C Larsen, J Lehmann, JH Levenson, D Logan, B McMillan, JR Martel, H Mayer, F Medeiros, S Moroi, A Moyes, J Myers, J Nairn

© 2020 American Academy of Ophthalmology Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10- and 15-μg bimatoprost implant in subjects with open-angle glaucoma (OAG) and ocular hypertension (OHT) after initial an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c062a84d4d7b4dd145a591e52e4876fd

Qualitative Development of the Allergan Satisfaction with Treatment Experience Questionnaire (ASTEQ) Instrument, a Patient-Reported Outcome Measure in Glaucoma and Ocular Hypertension.

Autor: Evans RM; Medical Center Ophthalmology Associates, San Antonio, TX, USA., Gauthier M; Lumanity, Boston, MA, USA., Goodkin ML; Allergan (an AbbVie company), 2525 Dupont Drive, Irvine, CA, USA., Huang JT; Allergan (an AbbVie company), 2525 Dupont Drive, Irvine, CA, USA. Joice.Huang@AbbVie.com.

Publikováno v: Ophthalmology and therapy [Ophthalmol Ther] 2024 Jan; Vol. 13 (1), pp. 71-92. Date of Electronic Publication: 2023 Sep 22.

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension.

Autor: Sun X; Eye & ENT Hospital of Fudan University, No. 83, Fenyang Road, Xuhui District, Shanghai, China. xhsun@shmu.edu.cn., Yao K; Eye Center of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China., Liu Q; Jiangsu Province Hospital, Nanjing, China., Zhang H; Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China., Xing X; Tianjin Medical University Eye Hospital, Tianjin, China., Fang A; Eye Hospital of Wenzhou Medical University, Wenzhou, China., Duan X; Second Xiangya Hospital of Central South University, Changsha, China., Yu M; Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China., Chen MY; Allergan (an AbbVie Company), Irvine, CA, USA.; Perfuse Therapeutics, Inc., San Francisco, CA, USA., Yang J; Allergan (an AbbVie Company), Irvine, CA, USA., Goodkin ML; Allergan (an AbbVie Company), Irvine, CA, USA.

Publikováno v: Ophthalmology and therapy [Ophthalmol Ther] 2023 Feb; Vol. 12 (1), pp. 341-353. Date of Electronic Publication: 2022 Nov 12.

Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty.

Autor: Ghosn C; Allergan, An AbbVie Company, Irvine, California, USA., Rajagopalan L; Allergan, An AbbVie Company, Irvine, California, USA., Ugarte S; Allergan, An AbbVie Company, Irvine, California, USA., Mistry S; Allergan, An AbbVie Company, Irvine, California, USA., Orilla W; Allergan, An AbbVie Company, Irvine, California, USA., Goodkin ML; Allergan, An AbbVie Company, Irvine, California, USA., Robinson MR; Allergan, An AbbVie Company, Irvine, California, USA., Engles M; Allergan, An AbbVie Company, Irvine, California, USA., Dibas M; Allergan, An AbbVie Company, Irvine, California, USA.

Publikováno v: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2022 May; Vol. 38 (4), pp. 311-318. Date of Electronic Publication: 2022 Apr 18.

Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).

Autor: Medeiros FA; Department of Ophthalmology, Duke University, Durham, North Carolina., Walters TR; Keystone Research, Ltd., Austin, Texas., Kolko M; Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup, Denmark; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark., Coote M; Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia., Bejanian M; Allergan plc, Irvine, California., Goodkin ML; Allergan plc, Irvine, California., Guo Q; Allergan plc, Irvine, California., Zhang J; Allergan plc, Madison, New Jersey., Robinson MR; Allergan plc, Irvine, California. Electronic address: Robinson_Michael@Allergan.com., Weinreb RN; Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California, San Diego, California.

Publikováno v: Ophthalmology [Ophthalmology] 2020 Dec; Vol. 127 (12), pp. 1627-1641. Date of Electronic Publication: 2020 Jun 13.